Enjoy complimentary customisation on priority with our Enterprise License!
The Global Addiction Therapeutics Market size is forecast to increase by USD 9.86 billion at a CAGR of 7.65% between 2022 and 2027. The market is driven by various factors, including the widespread consumption of alcohol, tobacco, and opioid products globally. With the approval of new drugs and the introduction of digital therapeutics, there is a growing arsenal of treatments available to combat addiction. Additionally, initiatives aimed at increasing awareness and addressing addiction are contributing to the market's growth, offering hope for individuals struggling with substance abuse disorders. This market research report also includes an in-depth analysis of drivers, trends, and challenges.
To learn more about this report, Request Free Sample
The market encompasses a range of treatments designed to address various types of addictions, including alcohol, cravings, behavior, spirits, statistics, and treatments. These therapeutics aim to help individuals overcome their dependencies and improve their overall well-being. The market includes innovative approaches such as research and development of new treatments, global sales of alcoholics and other addictive substances, medicinal interventions like Adicticiontics and InnoVative treatments, and various therapies like Cognitive-behavioral therapy, Support groups, and 12-step programs. The market is expanding as the global burden of substance abuse and addiction continues to rise, necessitating effective therapeutic interventions. The market is expected to show significant growth in the coming years due to increasing awareness, advancements in technology, and a growing need for effective addiction treatments.
The market encompasses a range of substances and treatments used to address various addictive disorders. These disorders can include substance addictions, such as those to alcohol, drugs, or nicotine, as well as behavioral addictions, like gambling or internet use. The market includes a diverse array of pharmaceutical interventions, such as methadone and buprenorphine for opioid addiction, and acamprosate and disulfiram for alcohol use disorders. Additionally, behavioral therapies, like cognitive-behavioral therapy and contingency management, are commonly used in the treatment of addictions. The market is driven by the growing prevalence of addictive disorders worldwide, as well as increasing awareness and acceptance of the need for effective treatment. The use of subsidies and insurance coverage for addiction treatment is also a significant factor in market growth. The market is expected to continue expanding in the coming years, as new treatments and interventions are developed and the stigma surrounding addiction continues to decrease. Our researchers studied the data for years, with 2022 as the base year, and 2023 as the estimated year, and presented the key drivers, trends, and challenges for the market.
One of the key factors driving growth in the market is the high consumption of alcohol, tobacco, and opioid products. The high consumption of alcohol, tobacco, and opioids globally drives the growth of the market. Despite increasing awareness about and stringent regulations on the consumption of these products, the market has witnessed an increase in the consumption of alcohol, opioids, and tobacco products. Opioids are a type of narcotic pain medication that is available as a therapy for the treatment of moderate-to-severe pain in many developed countries.
However, the misuse and abuse of opioids lead to opioid tolerance and addiction. The high consumption of alcohol, tobacco, and opioid products on a daily basis can lead to a strong desire or sense of compulsion to consume the substance. This results in complications in controlling substance use behavior in terms of its onset, termination, and levels of use, which leads to substance use disorder, also known as substance dependency. Owing to the high consumption of these substances, the prevalence of substance use disorders has increased globally. Hence, the high consumption of these substances increases the prevalence of addiction globally, thereby driving the market growth.
The increasing R&D of novel drugs is another factor supporting the market share growth in coming years. Due to the increasing consumption of alcohol, tobacco, and opioid products, the demand for novel therapeutics to treat substance use disorders has increased. Therefore, several companies are focusing on the development of novel therapeutics to treat substance use disorders.
Opiant Pharmaceuticals is developing OPNT002, nasal naltrexone, which produces rapid and strong increases in the plasma level and blocks the opioid receptor. As per the studies, OPNT002 offers some significant advantages over current treatment options by addressing the challenges faced by alcohol use disorder patients.
Adial Pharmaceutical is developing AD04 (ondansetron), a genetically targeted therapeutic agent for alcohol use disorder. AD04 can be used to treat other addictive disorders, such as opioid use disorder, obesity, and smoking MediciNova is developing MN-166 (ibudilast) to treat methamphetamine addiction. The company has completed a Phase II study of MN-166 for methamphetamine dependence. Amygdala Neurosciences is also developing ANS-6637, an oral aldehyde dehydrogenase 2 inhibitor. The drug modifies dopaminergic tone in the brain by preventing abnormal dopamine surges that drive craving without changing basal dopamine levels. The strong R&D and pipeline of addiction therapeutics are expected to drive the growth of the global market during the forecast period.
The presence of generics will be a major challenge for the market during the forecast period. The presence of generic drugs impacts the market, as the price of generic drugs is almost half the price of branded drugs. With an increase in the number of ANDA approvals, more generic drug manufacturers have entered the market, which is intensifying the competition in the market. The competition among generic drug makers is based on the low prices of generic drugs. The entry of generic drugs into the market leads to price wars that reduce drug prices. This impacts the overall market growth, as a reduction in drug prices leads to less revenue generation in the market.
The global market has the presence of branded and generic drug manufacturers. Owing to the loss of patents, many generic drug manufacturers, such as Cipla, Mylan, Teva Pharmaceutical, and InnoPharma Inc., have received generic drug approvals from the US FDA to market generic drugs such as acamprosate calcium. Since several generic manufacturers have entered the market, generic drugs have become more affordable than branded drugs. Thus, patent expiry and the growing penetration of generic drugs may impede the growth of the global addiction therapeutics market during the forecast period.
Our market reports analyze the life cycle of the global addictions therapeutics market from the innovator’s stage to the laggard’s stage. The report illustrates the lifecycle of the market, focusing on the adoption rates of the major regions such as the US, Canada, Germany, the UK, and France. Our researchers have included key purchase criteria, adoption rates, adoption lifecycles, and drivers of price sensitivity to help companies evaluate and develop growth strategies for 2022-2027.
Market Customer Landscape
This market research and growth report extensively covers market segmentation by distribution channel (hospital pharmacy, retail pharmacy, and others), type (alcohol addiction therapeutics, tobacco addiction therapeutics, and drug addiction therapeutics), and geography (North America, Europe, Asia, and the Rest of World (ROW)). In the distribution channel segment of the market, a multifaceted approach is adopted to address the diverse needs of individuals grappling with substance abuse disorders. Traditional channels such as medical stores play a pivotal role in providing access to medications targeting addictive substances, including synthetic drugs and new psychoactive substances. Moreover, rehabilitation facilities serve as essential outlets for comprehensive treatment, offering both medicinal and psychotherapeutic interventions. With the advent of telehealth services, individuals can access addiction treatment remotely, ensuring the widespread availability of support services. Innovative therapy adoption, driven by neuroscientific advances and technological advancements in diagnostics, is reshaping the landscape of addiction treatment. Additionally, collaborations between pharmaceutical companies and healthcare providers foster the development of novel therapies and enhance the efficacy of existing treatments. The legalization of marijuana prompts heightened drug awareness campaigns, emphasizing the importance of early intervention and treatment. Insights from organizations like Statistics Canada shed light on alcohol consumption patterns, guiding the allocation of resources and healthcare expenditure towards addiction treatment initiatives. Despite challenges such as alcohol cravings, insomnia, anxiety, and restlessness, concerted efforts across various distribution channels aim to mitigate the impact of substance abuse disorders and promote holistic recovery.
The market share growth by the hospital pharmacy segment will be significant during the forecast period. Hospital pharmacy is an important distribution channel for the global market. The hospital pharmacy segment accounts for a significant share of the market, owing to a wider range of facilities and advanced infrastructure to cater to the different needs of patients. Hospital groups or multi-specialty or super-speciality hospitals play an important role in terms of sales in this market. These hospitals are benefitted due to the availability of extensive inpatient and outpatient services, which help them generate high revenue. Owing to the good discounts, improving reimbursement, and the growing number of drug addicts, hospital pharmacies experience increasing demand. These factors will positively impact the growth of the hospital pharmacy segment of the global market during the forecast period.
Get a glance at the market contribution of various segments by View a PDF Sample
The hospital pharmacy segment showed a gradual increase in the demands for construction and other factors. In 2017, the market size was USD 8.16 billion and slightly increased by the end of 2021. Owing to the good discounts, improving reimbursement, and the growing number of drug addicts, hospital pharmacies experience increasing demand. These factors will positively impact the growth of the hospital pharmacy segment of the global market during the forecast period.
For more insights on the market share of various regions View PDF Sample now!
North America is projected to contribute 45% by 2027. Technavio’s analysts have elaborately explained the regional trends and drivers that shape the market during the forecast period.
The market in North America is significant due to the high prevalence of substance use disorders, particularly with amphetamines, alcohol, opioids, tobacco, marijuana, and cocaine. Mental disorders increase the likelihood of addiction to these substances and behaviors. Addicted individuals experience compulsive drug seeking, leading to harmful consequences. Drug treatment is essential for managing addiction, which can be a chronic disorder with occasional relapses. Alcohol use disorder and opioid addiction are common, while tobacco use and passive smoke exposure also contribute. Rehabilitation programs offer various treatments in different settings, including short-term and long-term processes, multiple interventions, and regular monitoring to prevent drug overdosing. Americans struggle with marijuana use and cocaine use, among other substances. Treatment is a long-term process requiring ongoing care and support for patients.
Companies are implementing various strategies, such as strategic alliances, partnerships, mergers and acquisitions, geographical expansion, and product/service launches, to enhance their presence in the market.
Alkermes Public. - Alkermes Public Ltd. Co. is a public company headquartered in Ireland. It is a global company generating USD 1,173.75 million in revenues and has around 2,211 employees. Its revenue from the market contributes to its overall revenues along with its other offerings, but it is not a key revenue stream for the company. The company is focused on developing innovative medicines that aim to address the unmet needs of people living with serious mental illness, addiction, and cancer. In April, the company announced the agreement with Sarissa Capital Management LP, a beneficial owner of approximately 5% of the company's outstanding ordinary shares.
We also have detailed analyses of the market’s competitive landscape and offer information on 20 market companies, such as
Our analysts have conducted an internal and external analysis of companies to help companies understand the wider business environment as well as the strength and weaknesses of key market players. If a vendor is focused only on the market then it is classified as a pure-play vendor. On the other hand, a vendor with interests in multiple industries is classified as a diversified vendor. The external analysis is a qualitative assessment of the ability of a vendor to impact the market through its actions. Dominant companies can impact the market significantly, while a weak vendor has no ability to influence the market dynamics.
The market undergoes transformation amidst shifting societal attitudes and evolving healthcare landscapes. With increasing concerns over substance abuse disorders and the legalization of marijuana, there's a growing emphasis on drug awareness campaigns and the management of synthetic drugs and new psychoactive substances. Rehabilitation facilities and telehealth services play vital roles in providing support and treatment. Technological advancements in diagnostics and neuroscientific advances facilitate more targeted interventions. Partnerships with pharmaceutical companies drive innovative therapies for addressing alcohol consumption and related issues like insomnia, anxiety, and restlessness. Market dynamics, including alcoholic beverage sales and global healthcare expenditure, influence the adoption of innovative treatments and the delivery of healthcare services for effective medicinal and psychotherapeutic treatment.
The market is shaped by partnerships and collaborations among various stakeholders, including medical stores and regulatory bodies like Statistics Canada. With a focus on addressing addiction to substances like ethyl alcohol, glutamate, and gamma-aminobutyric acid, innovative therapies are being adopted at an accelerated pace. These therapies encompass both medicinal treatment and psychotherapeutic approaches, catering to diverse needs. Market trends, such as fluctuations in wine sales, beer sales, spirits sales, and ciders and coolers sales, reflect changing consumption patterns and influence treatment strategies. As the market evolves, there's a concerted effort towards enhancing therapy adoption and improving outcomes for individuals grappling with addiction, driving advancements in both pharmacological and behavioral interventions.
Our market research report forecasts revenue growth at global, regional & country levels and provides an analysis of the latest trends and growth opportunities from 2017 to 2027.
Market Scope |
|
Report Coverage |
Details |
Page number |
165 |
Base year |
2022 |
Historical year |
2017-2021 |
Forecast period |
2023-2027 |
Growth momentum & CAGR |
Accelerate at a CAGR of 7.65% |
Market growth 2023-2027 |
USD 9.86 billion |
Market structure |
Fragmented |
YoY growth (%) |
6.56% |
Regional analysis |
North America, Europe, Asia, and Rest of World (ROW) |
Performing market contribution |
North America at 45% |
Key consumer countries |
US, Canada, Germany, UK, and France |
Competitive landscape |
Leading companies, Competitive Strategies, Consumer engagement scope |
Key companies profiled |
Alkermes Public Ltd. Co., Amneal Pharmaceuticals Inc., Aphios Corp., Braeburn Inc., Emergent BioSolutions Inc., GlaxoSmithKline Plc, Glenmark Pharmaceuticals Ltd., Hikma Pharmaceuticals Plc, Indivior Plc, Johnson and Johnson, Kaleo Inc., Mallinckrodt Plc, Orexo AB, Otsuka Holdings Co. Ltd., Pfizer Inc., Purdue Pharma LP, Sun Pharmaceutical Industries Ltd., Teva Pharmaceutical Industries Ltd., Titan Pharmaceuticals Inc., and Viatris Inc. |
Market Dynamics |
Parent market analysis, Market growth inducers and obstacles, Fast-growing and slow-growing segment analysis, COVID-19 impact and recovery analysis and future consumer dynamics, and Market condition analysis for the forecast period. |
Customization purview |
If our market report has not included the data that you are looking for, you can reach out to our analysts and get segments customized. |
We can help! Our analysts can customize this market research report to meet your requirements. Get in touch
1 Executive Summary
2 Market Landscape
3 Market Sizing
4 Historic Market Size
5 Five Forces Analysis
6 Market Segmentation by Distribution Channel
7 Market Segmentation by Type
8 Customer Landscape
9 Geographic Landscape
10 Drivers, Challenges, and Trends
11 Vendor Landscape
12 Vendor Analysis
13 Appendix
Get lifetime access to our
Technavio Insights
Cookie Policy
The Site uses cookies to record users' preferences in relation to the functionality of accessibility. We, our Affiliates, and our Vendors may store and access cookies on a device, and process personal data including unique identifiers sent by a device, to personalise content, tailor, and report on advertising and to analyse our traffic. By clicking “I’m fine with this”, you are allowing the use of these cookies. Please refer to the help guide of your browser for further information on cookies, including how to disable them. Review our Privacy & Cookie Notice.